An Experimental Pediatric Cancer Treatment Shows Promise in New Research
The treatment eliminated a boy's tumors with a single infusion.
In a groundbreaking development for pediatric cancer treatment, a 7-year-old German boy was recently diagnosed with kidney cancer and managed to live a relatively normal life, avidly cycling. Despite initial success in treating the cancer, it returned and spread to multiple organs, including the brain, leaving the boy with no further treatment options by the age of 17.
Dr. Christian Seitz, head of the Cell and Gene Therapy Program at Hopp Children's Cancer Center in Heidelberg, shares that the boy's cancer possessed specific markers that could be targeted by immune cells known as T-cells.
In a new study published in the New England Journal of Medicine, the team utilized an experimental approach called T-cell receptor-engineered therapy, which focuses on targeting proteins within the cancer cell rather than the surface proteins. Although this type of therapy is not typically effective for solid tumors, the team decided to proceed. The boy received a single infusion of T-cells in 2025, resulting in a complete remission and currently no detectable signs of cancer, even after a year of follow-up.
This approach of using T-cell receptor-engineered therapy opens up new possibilities for treating cancers that were previously considered difficult to target with engineered immune cell therapies. While the treatment had a challenging aftermath for the boy, requiring hospitalization for several weeks, his recovery has been remarkable, with all tumor metastases vanishing and the remaining tumors significantly shrinking.
The boy now possesses T-cells that can hunt down the PRAME protein, potentially enabling his body to combat any future cancer recurrence. This promising research, led by Dr. Seitz and his team, offers hope for other pediatric cancer patients with challenging tumors, paving the way for tailored immune cell treatments in the future.
Written by urgent.news from Time's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
